What does STERIGENICS do?

STERIGENICS is an engineering firm in Leuven. Public Limited, started on 30 September 1985, 1 establishment.

What is the address of STERIGENICS?

The registered office of STERIGENICS is located at Vaartdijk 3 box 302, 3018 Leuven.

Is STERIGENICS still active?

Yes. According to the CBE (29 October 2026) STERIGENICS is active, legal situation “Normale toestand”, started on 30 September 1985.

Is STERIGENICS registered on Peppol?

Yes, STERIGENICS is registered on the Peppol network with ID 0208:0427835425.

What is the enterprise number of STERIGENICS?

The enterprise number of STERIGENICS is BE0427835425.

When was STERIGENICS founded?

STERIGENICS was founded on 30 September 1985.

Who are the directors of STERIGENICS?

According to the 2025 annual accounts, the directors of STERIGENICS are: Ronald Asselberghs, Pontus Rundstrom Lars, Robin Van Den Bergh.

Is STERIGENICS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 September 1985; 4 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did STERIGENICS make in 2025?

STERIGENICS posted a profit after taxes of € 93,912,311 in financial year 2025.

How much does an employee at STERIGENICS earn?

The average wage cost per full-time employee at STERIGENICS was € 223,400 in 2025: staff costs of € 8.5 million for 38.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does STERIGENICS have?

According to the 2025 annual accounts, STERIGENICS has 38.1 full-time equivalents (FTE).

STERIGENICS (Public Limited) - Leuven - BE0427835425

Dossier STERIGENICS, printed on 29 October 2026 from databakkes.be/en/0427835425/sterigenics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.
Busy address KBO

31 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

STERIGENICS from Leuven, company number BE0427835425, closed financial year 2025 with a result of € 93.9 million after tax. Compared with financial year 2024, the result moved from € 375.8 million to € 93.9 million. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.

What it is worth Healthy

€ 469.5 million

▼ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 93.9 million

▼ 75% vs 2024

Profit after tax over the fiscal year.

Where the profit goes Pays out

€ 97.6 million paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

38.1

▲ 4.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 8.4 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 8.5 million

▲ 9% vs 2024

€ 223,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,782

▼ 54% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 90.1 million

▼ 18% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 183,525

▼ 20% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 8 days on average.

Taxes and wages

€ 2 million

▲ 32% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Profit after taxes	€ -1,675,804 Profit after taxes 2022: € -1,675,804 First fiscal year in the series	€ 2,382,743 Profit after taxes 2023: € 2,382,743 ▲ € 4.1 million vs 2022 (€ -1,675,804) Favourable step	€ 375,822,992 Profit after taxes 2024: € 375,822,992 ▲ € 373.4 million vs 2023 (€ 2,382,743) Favourable step	€ 93,912,311 Profit after taxes 2025: € 93,912,311 ▼ 75% vs 2024 (€ 375,822,992) Unfavourable step	▼ 75%
Equity	€ -13,965,045 Equity 2022: € -13,965,045 First fiscal year in the series	€ -11,582,301 Equity 2023: € -11,582,301 ▲ € 2.4 million vs 2022 (€ -13,965,045) Favourable step	€ 473,152,288 Equity 2024: € 473,152,288 ▲ € 484.7 million vs 2023 (€ -11,582,301) Favourable step	€ 469,472,261 Equity 2025: € 469,472,261 ▼ 1% vs 2024 (€ 473,152,288) Unfavourable step	▼ 1%
Total debts	€ 106,554,019 Total debts 2022: € 106,554,019 First fiscal year in the series	€ 106,762,024 Total debts 2023: € 106,762,024 Unchanged (€ 106,554,019) Unfavourable step	€ 119,481,458 Total debts 2024: € 119,481,458 ▲ 12% vs 2023 (€ 106,762,024) Unfavourable step	€ 125,305,113 Total debts 2025: € 125,305,113 ▲ 5% vs 2024 (€ 119,481,458) Unfavourable step	▲ 5%
Cash	€ 67 Cash 2022: € 67 First fiscal year in the series	€ 12 Cash 2023: € 12 ▼ 82% vs 2022 (€ 67) Unfavourable step	-	-
Retained profit	€ -26,416,045 Retained profit 2022: € -26,416,045 First fiscal year in the series	€ -24,033,301 Retained profit 2023: € -24,033,301 ▲ € 2.4 million vs 2022 (€ -26,416,045) Favourable step	€ 351,789,691 Retained profit 2024: € 351,789,691 ▲ € 375.8 million vs 2023 (€ -24,033,301) Favourable step	€ 348,109,663 Retained profit 2025: € 348,109,663 ▼ 1% vs 2024 (€ 351,789,691) Unfavourable step	▼ 1%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 97,592,339 Dividend 2025: € 97,592,339 Unchanged (€ 0) Unchanged
Bank debt	€ 93,875,056 Bank debt 2022: € 93,875,056 First fiscal year in the series	€ 100,332,627 Bank debt 2023: € 100,332,627 ▲ 7% vs 2022 (€ 93,875,056) Unfavourable step	€ 110,181,973 Bank debt 2024: € 110,181,973 ▲ 10% vs 2023 (€ 100,332,627) Unfavourable step	€ 90,089,405 Bank debt 2025: € 90,089,405 ▼ 18% vs 2024 (€ 110,181,973) Favourable step	▼ 18%
Balance sheet total	€ 94,888,975 Balance sheet total 2022: € 94,888,975 First fiscal year in the series	€ 97,479,722 Balance sheet total 2023: € 97,479,722 ▲ 3% vs 2022 (€ 94,888,975) Unchanged	€ 592,633,746 Balance sheet total 2024: € 592,633,746 ▲ € 495.2 million vs 2023 (€ 97,479,722) Unchanged	€ 594,777,374 Balance sheet total 2025: € 594,777,374 Unchanged (€ 592,633,746) Unchanged
Employees (FTE)	31.7 Employees (FTE) 2022: 31.7 First fiscal year in the series	30.6 Employees (FTE) 2023: 30.6 ▼ 1.1 vs 2022 (31.7) Unchanged	33.6 Employees (FTE) 2024: 33.6 ▲ 3 vs 2023 (30.6) Unchanged	38.1 Employees (FTE) 2025: 38.1 ▲ 4.5 vs 2024 (33.6) Unchanged	▲ 4.5

Key figures of STERIGENICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to STERIGENICS?

What happened at STERIGENICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 Ronald Asselberghs stepped down as director. NBB
2031 Robin Van Den Bergh stepped down as director. NBB
Jul 27, 2026 New annual accounts for financial year 2025: profit of € 93.9 million (▼ 75% vs 2024). Source: NBB ↗
2025 Ronald Asselberghs became a director. NBB
2025 Pontus Rundstrom Lars stepped down as director. NBB
2025 Pontus Rundstrom Lars became a director. NBB
2025 Robin Van Den Bergh became a director. NBB
Oct 1, 1985 New establishment in Leuven. KBO

In short

From € 1.7 million loss in 2022 to € 93.9 million profit in 2025.

Paid € 90,945 in corporate taxes since 2022.

Best year ever: 2024, with € 375.8 million profit.

Paid out € 97.6 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Sotera Health Holdings LLC 100%

STERIGENICS

STERIGENICS SHANGHAI ETO Ltd. 100%

Nelson Labs 99%

The shares are held by Sotera Health Holdings LLC (100%). It owns 100% of STERIGENICS SHANGHAI ETO Ltd. and 99% of Nelson Labs itself.

Directors

According to the 2025 annual accounts

Ronald Asselberghs

Director

since 2025 · until 2031

Pontus Rundstrom Lars

Director

since 2025 · until 2025

Robin Van Den Bergh

Director

Also active at: STERIGENICS BELGIUM (Petit Rechain)

since 2025 · until 2031

Shareholders

Sotera Health Holdings LLC

100%

Participations

STERIGENICS SHANGHAI ETO Ltd.

100%

Nelson Labs

99%

Establishments

Establishment units

Physical locations of this company

Registered office

Vaartdijk 3 box 302

3018 Leuven

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.

All companies at this address →

DIMA

€ 43,574 gross margin · 2025

REMY COMMUNICATION

€ 563,687 gross margin · 2025

REGIONALE OMROEP BRABANT

€ 669,322 gross margin · 2025

ELSYCA

€ 3.5 million gross margin · 2025

HOMO SAPIENS SAPIENS

€ 454,215 gross margin · 2025

+26 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0427.835.425

VAT number

BE 0427.835.425

Registered office

Vaartdijk 3 bus 302, 3018 Leuven

Names & denominations

STERIGENICS

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

30 September 1985

Peppol

Active · Active since 2 Jan 2026

Activities · NACE

Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts

Technische studiën en ingenieursactiviteiten

Andere reinigingsactiviteiten

Industriële reiniging

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

STERIGENICS

Warning lights

Financials

What happened to STERIGENICS?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions